You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 98 No. 2, AUGUST 1956 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (13)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Drug Therapy (Mecamylamine) of Hypertension

III. Results with Mecamylamine, a Completely Absorbed Ganglionic Blocking Agent

JOHN H. MOYER, M.D.; RALPH FORD, M.D.; EDWARD DENNIS, M.D.; COLEMAN CAPLOVITZ, M.D.; ROBERT HERSHBERGER, M.D.; PAUL K. CONNER, M.D.; SAM KINARD, M.D.; ROBERT McCONN, M.D.

AMA Arch Intern Med. 1956;98(2):187-210.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Ganglionic blocking agents appear to be the most potent therapeutic agents for reducing the blood pressure in patients with severe hypertension. However, the orthostatic effect and the variability in blood pressure response to currently available ganglionic blocking agents are the most serious limiting factors in the use of these agents and may completely prohibit their use in some patients. Concurrent administration of rauwolfia, which depresses the sympathetic nervous system in the brain, partially stabilizes the blood pressure response. However, even then extreme variability frequently exists, apparently due to incomplete and variable absorption of these agents (hexamethonium and pentolinium) from the gastrointestinal tract.*

Recently another long-acting gangionic blocking agent has become available for clinical trial.{dagger} This compound, mecamy- lamine,{ddagger} is a secondary amine (rather than a quaternary compound) which is completely absorbed from the gastrointestinal tract. For this reason it has been investigated as a therapeutic agent for reducing the blood . . . [Full Text PDF of this Article]


Author Affiliations

Houston

From the Departments of Pharmacology and Medicine, Baylor University College of Medicine, and the Cardiac Clinic of the Jefferson Davis Hospital, the Hermann Hospital, and the Medical Service of the Veteran's Administration Hospital.


Footnotes

Submitted for publication Dec. 16, 1955.

Presented by Dr. Moyer at the annual meeting of the American Heart Association, New Orleans, Oct. 24, 1955.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1956 American Medical Association. All Rights Reserved.